SILVER SPRING
Xocova cleared for COVID-19 post-exposure prophylaxis
- Sponsor
- Shionogi & Co., Ltd.
- Drug
- Xocova · ensitrelvir
- Indication
- COVID-19 post-exposure prophylaxis
FDA approved Xocova (ensitrelvir) for post-exposure prophylaxis of COVID-19, marking the first oral option for this indication.
What this means
Xocova is an oral antiviral pill that blocks a key protein the COVID-19 virus needs to replicate. FDA approved Xocova for preventing COVID-19 in people who’ve been exposed to the virus but aren’t yet sick. This gives households and close contacts a convenient option to potentially avoid infection, joining vaccines and other preventive tools.